Investigational drugs in PTSD.

Summary

Post-traumatic stress disorder (PTSD) is complex and challenging, with only sertraline and paroxetine approved for treatment, both showing modest efficacy. Despite effective therapies, many patients still experience symptoms. Advances in understanding PTSD as a disorder of stress circuitry and memory are leading to new treatments. Notably, ketamine and MDMA-assisted psychotherapy show promise, but issues like patient selection and long-term safety remain. The field is evolving towards precision medicine to improve outcomes.

Study at a glance

Abstract

Post-traumatic stress disorder (PTSD) remains one of psychiatry's most challenging disorders, common, disabling, and biologically complex. Despite decades of research, only sertraline and paroxetine are FDA-approved, both with modest efficacy. Even first-line trauma-focused psychotherapies leave up to half of patients with persistent symptoms. However, advances in neurobiology are reframing PTSD as a disorder of maladaptive stress circuitry, neuroplasticity, and memory reconsolidation, opening new therapeutic possibilities. This comprehensive review examines current PTSD pharmacotherapy, emerging neurobiological targets, and investigational treatments, highlighting 45 actively enrolling clinical trials. Emerging approaches target the hypothalamic-pituitary-adrenal (HPA) axis, adrenergic signaling, glutamatergic/GABAergic systems, endocannabinoids, neuropeptides, and serotonergic-based psychedelics. Rapid-acting interventions represent a major advance in PTSD therapeutics. Ketamine produces symptom reductions within hours, MDMA-assisted psychotherapy has demonstrated Phase 3 efficacy, and neurosteroids offer novel approaches to targeting hyperarousal. However, questions remain regarding durability, optimal dosing, patient selection, precision approaches, and long-term safety. Several early-stage assets also show preliminary promise but require rigorous evaluation. At the same time, the development pipeline remains unforgiving: many mechanistically plausible candidates, from NK-1 antagonists to AMPA modulators, have failed in late-stage trials, often due to high placebo responses, patient heterogeneity despite subtype-specific medication targets, and translational gaps. Brexpiprazole's recent FDA rejection, despite supportive early data, underscores persistent regulatory hurdles. While traditional approaches remain standard of care, breakthrough therapies represent paradigm shifts toward disease modification. Future progress depends on biomarker-guided precision medicine, novel trial designs to mitigate placebo effects, and integration of pharmacologic innovations with evidence-based psychotherapies.